Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research UK, immatics Biotechnologies sign collaboration agreement to trial IMA950 vaccine for GMB

CANCER RESEARCH UK and Cancer Research Technology - the charity's development and commercialisation arm - have reached a collaboration agreement with immatics Biotechnologies to trial their new treatment vaccine, IMA950, for glioblastoma multiforme (GMB), one of the most common forms of brain cancer.

16 Feb 2010

Oncolytics Biotech receives U.K. MHRA approval for REOLYSIN combination Phase 3 trial

Oncolytics Biotech Inc. today announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that the Company previously reached an agreement on with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process.

16 Feb 2010

Accuray: Mount Vernon Cancer Centre acquires CyberKnife Robotic Radiosurgery System

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that Mount Vernon Cancer Centre in the United Kingdom has become the first National Health Service hospital to acquire a CyberKnife® Robotic Radiosurgery System.

16 Feb 2010

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.

16 Feb 2010

ERYtech Pharma announces collaborative research agreement with M. D. Anderson Cancer Center

ERYtech Pharma, a specialty pharma company located in France and in USA (Philadelphia), is pleased to announce a collaborative research agreement in the field of personalized medicine focusing on ERYtech’s flagship product, GRASPA®, which consists of red blood cell-encapsulated L-asparaginase (L-ASP).

15 Feb 2010

Structure of 'DNA repair engine' that reverses beneficial effects of chemotherapy deciphered

Cancer Research UK scientists have deciphered the first structure of 'a DNA repair engine' that reverses the beneficial effects of chemotherapy, according to research published in Nature Structural and Molecular Biology* today.

15 Feb 2010

Tobacco users with HPV-positive head and neck cancers at increased risk of recurrence

Patients with head and neck cancer linked to high risk human papillomavirus, or HPV, have worse outcomes if they are current or former tobacco users, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

15 Feb 2010

Viral Genetics: Company update

Our mission is to bring new drug compounds to the marketplace. And we've never been in a stronger position to deliver on that promise. We've built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer to clinical trials.

12 Feb 2010

Histone modifications associated with pancreatic cancer development and progression

Specific chemical modifications to proteins called histones, which are found in the nucleus of cells and act as spools around which DNA is wound, can be used to predict prognosis and response to treatment in subsets patients with pancreatic cancer, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found.

12 Feb 2010

New project to unravel secret lives of cancer cells may help produce new cancer therapies

A team of scientists from Princeton University and The Cancer Institute of New Jersey has embarked on a major new project to unravel the secret lives of cancer cells that go dormant and self-cannibalize to survive periods of stress. The work may help produce new cancer therapies to stem changes that render cancer cells dangerous and resistant to treatment.

12 Feb 2010

New screening system developed to discover molecules that block HCV life cycle

A newly designed system of identifying molecules for treating hepatitis C should enable scientists to discover novel and effective therapies for the dangerous and difficult-to-cure disease of the liver, says Zhilei Chen, a Texas A&M University assistant professor of chemical engineering who helped develop the screening system.

12 Feb 2010

British rhubarb could be a potential source of anti-cancer agent

Eating rhubarb baked in a crumble is not only tasty it may also be the best way to take advantage of its health benefits, and could lead to the development of new cancer treatments.

From Sheffield Hallam University 11 Feb 2010

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.

11 Feb 2010

ALSF commemorates "a decade of standing for hope" by holding high profile lemonade stands

Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) is commemorating "a decade of standing for hope" by holding a string of high profile lemonade stands, the first taking place at the Pro Bowl and Super Bowl. 2010 marks 10 years since cancer patient Alexandra "Alex" Scott (1996-2004) held her first front yard lemonade stand to find a cure for childhood cancer.

11 Feb 2010

Research study on epigenetic phenotypes published online in the Journal of Clinical Oncology

PrognosDx Health, Inc. announced today that in an independent research study published online in the Journal of Clinical Oncology, cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic cancer with distinct epigenetic phenotypes and clinical outcomes.

11 Feb 2010

'CARES by GSK' introduces oncology co-pay assistance program

GlaxoSmithKline today announced the launch of CARES by GSK, a comprehensive program that provides a single point of contact to GSK services and programs designed to improve access to GSK oncology and specialty medications. In addition to the comprehensive offerings that include specialty reimbursement services and free medicine, CARES by GSK now offers its first oncology co-pay assistance program to further help eligible patients with limited insurance coverage to have better access to GSK oral oncology and specialty medicines.

11 Feb 2010

Micromet outlines the design of registration study for blinatumomab in ALL

At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S.

11 Feb 2010

41st Annual Meeting on Women's Cancer to be hosted in San Francisco, California

The Society of Gynecologic Oncologists (SGO) will host its 41st Annual Meeting on Women's Cancer March 14-17, 2010 at the Moscone West Convention Center in San Francisco, California. This year's meeting will feature more than 434 scientific presentations in addition to lectures, workshops, symposia and postgraduate courses that focus on emerging science, clinical trials and treatment advances for physicians and health care professionals in the field of gynecologic oncology.

11 Feb 2010

CINJ researchers develop new vaccine strategy for pancreatic cancer

More than 42,500 people in the United States were diagnosed with pancreatic cancer last year and nearly 35,200 died from the disease, according to The American Cancer Society.

11 Feb 2010

New research suggests closantel drug may be useful in combating river blindness

Scientists at The Scripps Research Institute have discovered a potential new use for the drug closantel, currently the standard treatment for sheep and cattle infected with liver fluke. The new research suggests that the drug may be useful in combating river blindness, a tropical disease that is the world's second leading infectious cause of blindness for humans.

10 Feb 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research UK, immatics Biotechnologies sign collaboration agreement to trial IMA950 vaccine for GMB

Oncolytics Biotech receives U.K. MHRA approval for REOLYSIN combination Phase 3 trial

Accuray: Mount Vernon Cancer Centre acquires CyberKnife Robotic Radiosurgery System

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

ERYtech Pharma announces collaborative research agreement with M. D. Anderson Cancer Center

Structure of 'DNA repair engine' that reverses beneficial effects of chemotherapy deciphered

Tobacco users with HPV-positive head and neck cancers at increased risk of recurrence

Viral Genetics: Company update

Histone modifications associated with pancreatic cancer development and progression

New project to unravel secret lives of cancer cells may help produce new cancer therapies

New screening system developed to discover molecules that block HCV life cycle

British rhubarb could be a potential source of anti-cancer agent

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

ALSF commemorates "a decade of standing for hope" by holding high profile lemonade stands

Research study on epigenetic phenotypes published online in the Journal of Clinical Oncology

'CARES by GSK' introduces oncology co-pay assistance program

Micromet outlines the design of registration study for blinatumomab in ALL

41st Annual Meeting on Women's Cancer to be hosted in San Francisco, California

CINJ researchers develop new vaccine strategy for pancreatic cancer

New research suggests closantel drug may be useful in combating river blindness

Cancer Research - Second Edition eBook

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Newsletters you may be interested in